Probing the pharmacology of the 5-HT1B receptor and its role in pulmonary disease
Lead Research Organisation:
University of Glasgow
Department Name: School of Life Sciences
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
| Description | 5HT1B antagonist can reverse pulmonary hypertension |
| Exploitation Route | Development of a 5HT1B antagonist for pulmonary hypertension |
| Sectors | Pharmaceuticals and Medical Biotechnology |
| Description | MRC project grant |
| Amount | £595,086 (GBP) |
| Funding ID | MR/N011112/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2016 |
| End | 04/2019 |
| Description | 5HT1B antagonists in PAH |
| Organisation | University of Cambridge |
| Department | Cambridge Enterprise |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Results of BBSRC Follow on Funds |
| Collaborator Contribution | Research |
| Impact | n/a |
| Start Year | 2010 |
| Description | miR96 and pulmonary hypertension |
| Organisation | United Therapeutics |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Building on our success with the MRC CiC award and the PhD studentship we were awarded a MRC project grant to further our studies into miR96 and PAH. This created discussions with United Therapeutics who supplemented tis study. |
| Collaborator Contribution | Provision of £79000 to cover costs of a patent and RNAseq |
| Impact | Too early |
| Start Year | 2016 |
| Description | ASPET award |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | 2017 Spector award and invited lecture presented at the ASPET Annual Meeting at EB2017, April 22-26 in Chicago. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Berlin: 4th Annual Drug Discovery and Development Symposium For Pulmonary Hypertension which will be held at the Hotel Hilton in Berlin, Germany on July 10-11, 2017. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Drug discovery presentation: serotonin and PAH |
| Year(s) Of Engagement Activity | 2017 |